openPR Logo
Press release

HIV Drug Market Analysis By 2022 - Boehringer Ingelheim International GmbH Merck & Co., Inc. ViiV Healthcare AbbVie F. Hoffmann-La Roche Ltd. Teva Pharmaceutical Industries Ltd. Bristol-Myers Squibb Gilead Sciences, Inc. Johnson & Johnson Cipla Limited

10-17-2018 10:27 AM CET | Health & Medicine

Press release from: Allied Market Research

HIV Drug Market Analysis By 2022 - Boehringer Ingelheim

HIV Drug Market Overview

Global HIV Drug Market was valued at $20,448 million in 2015 and is expected to garner $26,458 million by 2022, registering a CAGR of 3.7% during the forecast period 2016-2022. Human immunodeficiency virus (HIV) is one of the most infectious diseases with around 36.7 million people suffering by the end of 2015, according to The Joint United Nations Programme on HIV/AIDS (UNAIDS).

Request For Sample Reports :
https://www.alliedmarketresearch.com/request-sample/1867

The major factors that boost the HIV drug market growth include increase in prevalence of HIV and rise in treatment & diagnosis rate. Moreover, there is an increase in the government initiative to increase awareness among people about HIV cause, symptoms, available treatment options, and the crucial role of these treatments in the control of HIV virus growth. Thus, rise in awareness through such government initiatives are also expected to drive the HIV drugs market. However, stringent government regulations for the approval and commercialization of HIV drugs is expected to restrain the industry growth.

Segment Review:

The global HIV drugs market is segmented by medication class and geography. On the basis of medication class, the industry is classified into multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), fusion inhibitors (FI), entry inhibitors, and HIV integrase stand transfer inhibitors. Among the medication class, the multi-class combination drugs hold the largest market share as it’s the most advanced technique used for the treatment of HIV infection. This is due to the increase in adoption of drugs from this medication class owing to their better results in the control of HIV & related coinfections and their ease in consumption & adherence.

Top Impacting Factors:

Increase in Number of HIV Infected Patients Worldwide

According to WHO, 36.7 million people were diagnosed with HIV/AIDS in 2015, whereas, 1.1 million people died of AIDS-related illness in the same year. The world has very high prevalence of people living with HIV owing to the various factors, such as lack of availability of medication for the treatment of HIV infection. In the emerging nations including sub-Saharan Africa, countries with low income do not have sufficient funds to buy high price drugs leading to increase in the population living with HIV.

Initiatives Taken By Various Government Associations To Raise Awareness About Diagnosis and Management of HIV/AIDS

The federal government agencies, and various associations across the globe have introduced many initiatives and education campaigns for community awareness to address HIV prevention, treatment, and care. For instance, the U.S. government launched the National HIV/AIDS Strategy, a five year initiative with various strategic goals, in 2010. These include the plan to reduce incidence of HIV infections and to increase the access to treatment. This National HIV/AIDS Strategy was further extended by the government to 2020 in July 2015.
The increase in awareness among people regarding diagnosis and management of the diseases due to various initiatives increase the treatment rate and thus, this factor acts as an important driver for the growth of the HIV drug market.

Introduction of Generic Drugs of HIV Drugs

Generic drugs are the revised copy of the branded drugs with slight modifications in the ingredients and are launched in the market after the patent expiry of the branded drugs. Companies, such as Mylan Pharmaceuticals Inc., Hetero Labs Ltd., and other such companies majorly work on generic version of the HIV drugs, launching them at cheaper costs. Patent expiration of the blockbuster drugs helps introduce the generic version, which promotes generic drug pharmaceutical market growth. The adoption of generic HIV drugs is very high because they offer same treatment as branded drugs at a very lost cost and are highly preferred in low income regions, such as Africa.

Stringent Regulatory Requirements for the Approval and Commercialization of HIV Drugs

Each new HIV drug must go through the regulatory approval process and meet the standard requirements. This process is stringent and time-consuming. The commercialization and approval of these drugs is regulated by agencies, such as CE and FDA. The manufacturer must compile a file for every pipeline drug to include information, such as AIP (Application Integrity Policy), its use, and risk assessment while filling the drug for approval. It is also involved in drug manufacturing and development to establish licensing. Similarly, EMA protects public and animal health by ensuring safety of HIV drugs for human. These stringent regulatory standards and guidelines obstruct the entrance of new players in the market.

Increase in Number of Products in the Pipeline

Various pharma giants, such as Boehringer Ingelheim, Gilead Sciences, Inc., Merck & Co., Inc. GSK, Roche, and others are continuously involved in the drug development to offer better drugs for the treatment of HIV for complete cure and to provide products with very less or no side effects. These companies also utilize various innovative technologies, such as cell therapy and immunomodulation along with antivirals for the drug development. For instance, Bictegravir/F/TAF, F/TAF, GS-9620, which undergo clinical trials. This results in emergence of more effective treatments, showing quick results to treat HIV/AIDS. The launch of such innovative drugs in the market is expected to create the opportunities for HIV drugs market in the future.

Geographic Analysis:

The North American region accounted half of the share in the overall HIV drug market in 2015, and is expected to maintain this lead throughout the forecast period. The growth in the North American HIV drug market is attributed to well-established healthcare system, higher diagnosis & treatment rate, government funding for R&D, and increase in the adoption of advanced treatment options from HIV infected population. However, Asia-Pacific & LAMEA are projected to grow at a faster CAGR during the forecast period.

To Know More , Do Visit :
https://www.alliedmarketresearch.com/hiv-drugs-market

Hiv Drug Market Key Benefits:

The study provides an in-depth analysis of the HIV drugs market, with current trends and future estimations to elucidate the imminent investment pockets.

It presents a quantitative analysis from 2014 to 2022 to enable the stakeholders to capitalize on prevailing market opportunities.

Extensive analysis of the HIV drug market, by medication class, assists in the effective treatment of HIV/AIDS.

Key players are profiled and their strategies are analyzed thoroughly, which predicts the competitive outlook of the market.

Hiv Drug Market Key Segments:

By Medication Class

• Multi-Class Combination Drugs

Atripla
Complera
Prezcobix/Prezista
Stribild
Triumeq

• Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

Combivir
Emtriva
Epivir
Epzicom
Trizivir
Truvada
Viread

• Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

Edurant
Intelence
Rescriptor
Sustiva
Viramune (Immediate Release)

• Protease Inhibitors (PIs)

Aptivus
Crixivan
Kaletra
Lexiva
Norvir
Reyataz
Viracept

• Fusion Inhibitors (FI)

Fuzeon

• Entry Inhibitors

Selzentry

• HIV Integrase Stand Transfer Inhibitors.

Isentress
Tivicay

Request For Purchase Enquiry :
https://www.alliedmarketresearch.com/purchase-enquiry/1867

About Us:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release HIV Drug Market Analysis By 2022 - Boehringer Ingelheim International GmbH Merck & Co., Inc. ViiV Healthcare AbbVie F. Hoffmann-La Roche Ltd. Teva Pharmaceutical Industries Ltd. Bristol-Myers Squibb Gilead Sciences, Inc. Johnson & Johnson Cipla Limited here

News-ID: 1309284 • Views:

More Releases from Allied Market Research

Graphene Electronics Market With in-detailed Competitor Analysis, Forecast to 2032
Graphene Electronics Market With in-detailed Competitor Analysis, Forecast to 20 …
Allied Market Research published an exclusive report, titled, "Graphene Electronics Market Size, Share, Competitive Landscape and Trend Analysis Report by Product, By Industry Vertical : Global Opportunity Analysis and Industry Forecast, 2021-2031". The global graphene electronics market was valued at $270.8 million in 2021, and is projected to reach $5.2 billion by 2031, growing at a CAGR of 34.2% from 2022 to 2031 Download Research Report Sample & TOC : https://www.alliedmarketresearch.com/request-sample/142 The graphene
Lithium-Ion Battery Energy Storage System Market Size is projected to reach $17.1 billion by 2031 | Jakson Group, LG Electronics
Lithium-Ion Battery Energy Storage System Market Size is projected to reach $17. …
Allied Market Research published an exclusive report, titled, "Lithium-Ion Battery Energy Storage System Market Size, Share, Competitive Landscape and Trend Analysis Report by Connection Type, by Application : Global Opportunity Analysis and Industry Forecast, 2021-2031". The global lithium-ion battery energy storage system market was valued at $4.5 billion in 2021, and is projected to reach $17.1 billion by 2031, growing at a CAGR of 15% from 2022 to 2031. Download Research Report
Smart Railway Market Poised for Remarkable Growth, Reaching $38,469.7 million by 2027
Smart Railway Market Poised for Remarkable Growth, Reaching $38,469.7 million by …
𝐒𝐦𝐚𝐫𝐭 𝐑𝐚𝐢𝐥𝐰𝐚𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 by System (Passenger Information System, Rail & Freight Operations Management System, Smart Safety & Security Monitoring System, Rail communication & Networking System, Smart Ticketing System, Rail Analytics System, and Others) and Offering Type (Solutions, Components & Devices, and Services): Global Opportunity Analysis and Industry Forecast, 2020-2027" According to the report published by Allied Market Research, The global smart railway market size was valued at $18,304.8 million in
Odor Sensor Market Size is projected to reach $19.4 billion by 2031 | eNose Company, Odotech
Odor Sensor Market Size is projected to reach $19.4 billion by 2031 | eNose Comp …
Allied Market Research published an exclusive report, titled, "Odor Sensor Market Size, Share, Competitive Landscape and Trend Analysis Report by Sensor Type, by Instrument Type, by Application Areas, by End Use Industry : Global Opportunity Analysis and Industry Forecast, 2021-2031". The global odor sensor market size was valued at $1.5 billion in 2021, and is projected to reach $19.4 billion by 2031, growing at a CAGR of 29.4% from 2022 to

All 5 Releases


More Releases for HIV

HIV-Associated Lipodystrophy Treatment Market - Increasing prevalence of HIV is …
HIV-associated lipodystrophy also known as lipodystrophy is a syndrome that occurs in HIV-infected patients. It is characterized by loss of subcutaneous fat from face, buttocks, arms and legs. Although the exact cause of HIV-associated lipodystrophy is not fully elucidated, some research evidence reported that it occurs in HIV-infected patients who are under antiretroviral medications. According to an article published in National Center for Biotechnology Information (NCBI) in 2014, prevalence of
Global HIV Drugs Market | Global HIV Drugs Industry | Global HIV Drugs Market Re …
Human immunodeficiency Virus (HIV) could be a chronic and severe sickness which might be transferred from one person to a different through blood-to-blood and sexual contact. it's a deadly disease that attacks immune cells called CD-4 cells, creating body vulnerable to infections and alternative diseases. Over the years, the rising prevalence of HIV sickness worldwide has completely influenced the demand for HIV medicine. HIV medicine facilitate in preventing the multiplication
HIV Therapeutics Market– South Africa's Aspen launches three-in-one HIV drug
Recent Developments Aspen Pharma care, a South Africa’s drug maker has launched a triple combination of tablet for the treatment of HIV in the country where the HIV virus is the most prevalent. The company's new Emdolten drug is a once a day tablet which is in the form of dolutegravir, an antiretroviral medication that balances the drug’s resistance. The company has launched Aspen Stavudine which was its first generic ARV
HIV Vaccine Market HIV Vaccine Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents Introduction to Human Immunodeficiency Virus (HIV) Vaccines 1.1 Overview 1.2 Antiquity of HIV Vaccine Need for the Development of HIV Vaccine Primer of HIV inside the Body 3.1 Inclusion of HIV Virus into the System 3.2 Interaction of HIV with Host 3.3 Eradication of HIV Virus HIV Vaccine Development Process 4.1 Introduction
Global HIV Vaccine Market & HIV Vaccine Clinical Trial Outlook 2022
Worldwide, around the 35 Million of the people are currently infected with the HIV and about 30 Million of the people died because of the AIDS infection. There is no human example of clearing an HIV infection naturally. HIV virus makes copies of it very quickly, many types of HIV exist and new types of virus are continue to rise. Many scientists are still trying to understand the specific ways
Hidden HIV Revealed: New Insights Into Latent HIV Infections
In spite of ever more effective therapies, HIV keeps managing to survive in the body. A comprehensive project conducted by the Austrian Science Fund FWF has clarified the molecular processes which contribute to this effect. In the process, approaches were discovered for possible therapies to combat the hidden reservoir formed by the virus. Thanks to modern therapies, HIV infections have become controllable – but these treatments cannot provide a cure. Antiretroviral